Abstract:Allergic asthma is characterized by airway hyperresponsiveness, remodeling, and reversible airway obstruction. This is associated with an eosinophilic inflammation of the airways, caused by inhaled allergens such as house dust mite or grass pollen. The inhaled allergens trigger a type-2 inflammatory response with the involvement of innate lymphoid cells (ILC2) and Th2 cells, resulting in high immunoglobulin E (IgE) antibody production by B cells and mucus production by airway epithelial cells. As a consequence of the IgE production, subsequent allergen reexposure results in a classic allergic response with distinct early and late phases, both resulting in bronchoconstriction and shortness of breath. Allergen-specific immunotherapy (AIT) is the only treatment that is capable of modifying the immunological process underlying allergic responses including allergic asthma. Both subcutaneous AIT (SCIT) as well as sublingual AIT (SLIT) have shown clinical efficacy in long-term suppression of the allergic response. Although AIT treatments are very successful for rhinitis, application in asthma is hampered by variable efficacy, long duration of treatment, and risk of severe side effects. A more profound understanding of the mechanisms by which AIT induces tolerance to allergens in sensitized individuals is needed to be able to improve its efficacy. Mouse models have been very valuable in preclinical research for characterizing the mechanisms of desensitization in AIT and evaluating novel approaches to improve its efficacy. Here, we present a rapid and reproducible mouse model for allergen-specific immunotherapy. In this model, mice are sensitized with two injections of allergen adsorbed to aluminum hydroxide, followed by subcutaneous injections (SCIT) or sublingual administrations (SLIT) of allergen extracts as an immunotherapy treatment. Finally, mice are challenged by intranasal allergen administrations. We will also describe the protocols as well as the most important readout parameters for the measurements of invasive lung function, serum immunoglobulin levels, isolation of bronchoalveolar lavage fluid (BALF), and preparation of cytospin slides. Moreover, we describe how to perform ex vivo restimulation of lung single-cell suspensions with allergens, flow cytometry for identification of relevant immune cell populations, and ELISAs and Luminex assays for assessment of the cytokine concentrations in BALF and lung tissue.

Immunological effects of adjuvanted low‐dose allergoid allergen‐specific immunotherapy in experimental murine house dust mite allergy

Sublingual Immunotherapy of Atopic Dermatitis in Mite-Sensitized Patients: a Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study

Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Induction Of Cd4(+)Cd25(+)Foxp3(+)Il-10(+) T Cells In Hdm-Allergic Asthmatic Children With Or Without Sit

Effect of intralymphatic allergen-specific immunotherapy on house dust mite in a murine model of allergic rhinitis

Novel adjuvants in allergen-specific immunotherapy: where do we stand?

Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma

Immunotherapy for house-dust mite allergy

State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)

Immunotherapy of House Dust Mite Allergy

Activation of the aryl hydrocarbon receptor improves allergen-specific immunotherapy of murine allergic airway inflammation: a novel adjuvant option?

Safety and Immunogenicity of a Cluster Specific Immunotherapy in Children with Bronchial Asthma and Mite Allergy

Expanding Options in House Dust Mite Allergy Immunotherapy: Optimising Individual Patient Outcomes

Allergen immunotherapy in patients with atopic dermatitis allergic to house dust mite: A systematic review and meta-analysis

Effect and mechanism of allergen‐specific immunotherapy on small airway dysfunction in children with asthma

Effect of Specific Immunotherapy on the Expression of NKT Cells in House Dust Mite Extracts-Sensitized Murine Model

The Safety and Tolerability of a One Strength Dose-Escalation Scheme for Subcutaneous Immunotherapy with a Native House Dust Mite Extract in Chinese Children: A Multicenter, Randomized, Open Label Clinical Trial

Cost‐effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma

Immunological changes after ASIT in AD allergen-specific immunotherapy and their potential correlation with clinical response in patients with atopic dermatitis patients sensitized to house dust mite

Sialic acid-modified der p 2 allergen exerts immunomodulatory effects on human PBMCs